The impact of a whole foods dietary intervention on gastrointestinal symptoms, inflammation, and fecal microbiota in pediatric patients with cystic fibrosis: A pilot study.

Cystic fibrosis Diet Gastrointestinal symptoms Microbiome Nutrition

Journal

Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603

Informations de publication

Date de publication:
25 Sep 2024
Historique:
received: 13 05 2024
revised: 07 09 2024
accepted: 23 09 2024
medline: 9 10 2024
pubmed: 9 10 2024
entrez: 9 10 2024
Statut: aheadofprint

Résumé

Gastrointestinal (GI) complications are a significant source of morbidity for people with cystic fibrosis (PwCF). Historically, dietary recommendations in CF have focused on calories, typically emphasizing a high fat diet. The changing landscape of CF highlights the need to update this nutritional strategy. There is little research into how the quality of calories consumed by PwCF influences nutritional outcomes, GI symptoms, or likely contributors: intestinal inflammation and GI microbiology. We assessed the feasibility of a whole foods-based diet (WFD) and avoidance of ultra-processed foods, measuring safety/tolerability, adherence, and GI symptoms, as well as fecal measures of inflammation and microbiota among children with CF (CwCF) with GI symptoms. Single center, 4-week dietary intervention involving CwCF aged 5-14 years who screened positive on GI symptom questionnaire. Assessments included weight, symptom questionnaires and adverse events (AEs). Stool was analyzed for microbiota (16S rRNA) and calprotectin. 108 children were pre-screened, 9 enrolled and 8 initiated and completed the study. There were no significant changes in weight and no AEs. PEDS-QL GI identified overall improvement in symptoms. Certain symptom domains (constipation, diarrhea, gas/bloating, stomach pain and hurt) demonstrated significant improvement on the WFD. Of two participants with abnormal fecal calprotectin at enrollment, both exhibited decreased values on WFD. There was no significant change in microbiota diversity. A WFD diet was feasible and safe in CwCF. There was improvement in GI symptom scores based on both parent and child assessments. Larger studies are needed to further investigate effects on intestinal inflammation and microbiota.

Sections du résumé

BACKGROUND BACKGROUND
Gastrointestinal (GI) complications are a significant source of morbidity for people with cystic fibrosis (PwCF). Historically, dietary recommendations in CF have focused on calories, typically emphasizing a high fat diet. The changing landscape of CF highlights the need to update this nutritional strategy. There is little research into how the quality of calories consumed by PwCF influences nutritional outcomes, GI symptoms, or likely contributors: intestinal inflammation and GI microbiology. We assessed the feasibility of a whole foods-based diet (WFD) and avoidance of ultra-processed foods, measuring safety/tolerability, adherence, and GI symptoms, as well as fecal measures of inflammation and microbiota among children with CF (CwCF) with GI symptoms.
METHODS METHODS
Single center, 4-week dietary intervention involving CwCF aged 5-14 years who screened positive on GI symptom questionnaire. Assessments included weight, symptom questionnaires and adverse events (AEs). Stool was analyzed for microbiota (16S rRNA) and calprotectin.
RESULTS RESULTS
108 children were pre-screened, 9 enrolled and 8 initiated and completed the study. There were no significant changes in weight and no AEs. PEDS-QL GI identified overall improvement in symptoms. Certain symptom domains (constipation, diarrhea, gas/bloating, stomach pain and hurt) demonstrated significant improvement on the WFD. Of two participants with abnormal fecal calprotectin at enrollment, both exhibited decreased values on WFD. There was no significant change in microbiota diversity.
CONCLUSION CONCLUSIONS
A WFD diet was feasible and safe in CwCF. There was improvement in GI symptom scores based on both parent and child assessments. Larger studies are needed to further investigate effects on intestinal inflammation and microbiota.

Identifiants

pubmed: 39383549
pii: S0261-5614(24)00347-9
doi: 10.1016/j.clnu.2024.09.036
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

156-163

Informations de copyright

Copyright © 2024 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of interest The authors of this manuscript have no conflicts of interest to disclose.

Auteurs

Nicole Green (N)

Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, University of Washington School of Medicine, Seattle, WA, USA. Electronic address: nicole.green@seattlechildrens.org.

Carson Miller (C)

Department of Microbiology, University of Washington School of Medicine, Seattle, WA, USA.

David Suskind (D)

Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, University of Washington School of Medicine, Seattle, WA, USA.

Marshall Brown (M)

Seattle Children's Research Institute, Seattle, WA, USA.

Christopher Pope (C)

Department of Microbiology, University of Washington School of Medicine, Seattle, WA, USA.

Hillary Hayden (H)

Department of Microbiology, University of Washington School of Medicine, Seattle, WA, USA.

Sharon McNamara (S)

Seattle Children's Hospital, Seattle, WA, USA.

Anna Kanter (A)

Seattle Children's Hospital, Seattle, WA, USA.

Laura Nay (L)

Seattle Children's Hospital, Seattle, WA, USA.

Lucas Hoffman (L)

Department of Microbiology and Department of Pediatrics, Division of Pulmonary and Sleep Medicine, University of Washington School of Medicine, Seattle, WA, USA.

Margaret Rosenfeld (M)

Department of Epidemiology and Department of Pediatrics, Division of Pulmonary and Sleep Medicine, University of Washington School of Medicine, Seattle, WA, USA.

Classifications MeSH